Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 1.7% – What’s Next?

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s share price was down 1.7% during mid-day trading on Monday . The company traded as low as $1.16 and last traded at $1.17. Approximately 8,584 shares changed hands during trading, a decline of 84% from the average daily volume of 52,941 shares. The stock had previously closed at $1.19.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PSTV. Ascendiant Capital Markets decreased their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Plus Therapeutics in a report on Tuesday, November 26th.

Plus Therapeutics Price Performance

The firm has a 50 day moving average price of $1.21 and a 200-day moving average price of $1.40. The firm has a market cap of $6.90 million, a price-to-earnings ratio of -0.46 and a beta of 0.70.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.